The relationship of adipocytokine with the development of HIV-related lipodystrophy was investigated in a case-control study. Adipocytokine, lipid, and glycemic parameters were measured at every visit. Logistic regression analysis was used to assess the HIV-LD risk factors and the Spearman correlation coefficients test was used to assess the correlation between adiponectin with other metabolic variables. Most of the patients (96.3%) developed HIV-LD after month 12. Comparing the baseline adiponectin, the adiponectin concentration of the HIV-LD group rose by month 6 and began to decrease substantially by month 18; this reduction was maintained until month 30 (p < 0.05). Comparing the HIV-NLD group, the adiponectin concentration at months 18, 24, and 30 were significantly lower in the HIV-LD group. The leptin concentration of both the HIV-LD and HIV-NLD groups remained stable. Patients in the lower concentration of baseline adiponectin and greater adiponectin change rate at month 18 presented with increased odds ratio for HIV-LD. The adiponectin level had a correlation with serum triglycerides (r = −0.616, p < 0.0001), serum insulin concentration (r = −0.494, p = 0.001), and HDL-C (r = 0.673, p < 0.0001). The adiponectin concentration of HIV-LD began to decrease substantially by month 18. The lower baseline concentration of adiponectin and the greater change rate at month 18 were independent risk factors of HIV-LD. The adiponectin level had a correlation with serum triglycerides, serum insulin concentration, and HDL-C, suggesting that adiponectin may link the metabolic abnormalities and HIV-LD.
Get full access to this article
View all access options for this article.
References
1.
CarrA, SamarasK, ChisholmDJ, CooperDA. Abnormal fat distribution and use of protease inhibitors. Lancet, 1998; 351:1736.
2.
MallonPW, CooperDA, CarrAL. HIV-associated lipodystrophy. HIV Med, 2001; 2:166–173.
3.
DuranS, SavèsM, SpireB, CailletonV, SobelA, CarrieriP, SalmonD, MoattiJP, LeportC. the APROCO Study Group. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS, 2001; 15:2441–2444.
4.
d'ArminioA, SabinCA, PhillipsAN, ReissP, WeberR, KirkO, El-SadrW, De WitS, MateuS, PetoumenosK, DabisF, PradierC, MorfeldtL, LundgrenJD, Friis-MøllerN. the Writing Committee of the D:A:D: Study Group. Cardio- and cerebrovascular events in HIV-infected persons. AIDS, 2004; 18:1811–1817.
5.
Friis-MøllerN, SabinCA, WeberR, d'Arminio MonforteA, El-SadrWM, ReissP, ThiébautR, MorfeldtL, De WitS, PradierC, CalvoG, LawMG, KirkO, PhillipsAN, LundgrenJD. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med, 2003; 349:1993–2003.
6.
FRAM Study Investigators. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr, 2005; 40:121–131.
7.
FRAM Study Investigators. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr, 2006; 42:562–571.
8.
HaqueWA, ShimomuraI, MatsuzawaY, GargA. Serum adiponectin and leptin in patients with lipodystrophies. J Clin Endocrinol Metab, 2002; 87:2395–2398.
9.
SchwenkA. Methods of assessing body shape and composition in HIV-associated lipodystrophy. Curr Opin Infect Dis, 2002; 15:9–16.
10.
LichtensteinKA, DelaneyKM, ArmonC, WardDJ, MoormanAC, WoodKC, HolmbergSD. the HIV Outpatient Study Investigators. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr, 2003; 32:48–56.
11.
EstradaV, Martínez-LarradMT, González-SánchezJL, de VillarNG, ZabenaC, FernándezC, Serrano-RíosM. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metab Clin Exp, 2006; 55:940–945.
12.
LiM, WuCY, ZhanZW, LiXG, ZhangK, XiangHD. Leptin and clustering of the components of risk factors for metabolic syndrome. Zhonghua Yu Fang Yi Xue Za Zhi, 2004; 38:226–230.
13.
YinJH, LiM, YangJ, WuCY. Primary culture of human omental preadipocytes and study of their biological properties. Zhonghua Yi Xue Za Zhi, 2007; 27:838–841.
14.
XiaoX, ZhangZX, CohenHJ, WangH, LiW, WangT, XuT, LiuA, GaiMY, YingS, SchmitzO, YiZ. Evidence of a relationship between infant birth weight and later diabetes and impaired glucose regulation in a Chinese population. Diabetes Care, 2008; 31:483–487.
15.
ChenD, AnoopM, GargA. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab, 2002; 87:4845–4856.
16.
TongQ, SankaléJL, HadiganCM, TanG, RosenbergES, KankiPJ, GrinspoonSK, HotamisligilGS. Regulation of adiponectin in human immunodeficiency virus-infected patients: Relationship to body composition and metabolic indices. J Clin Endocrinol Metab, 2003; 88:1559–1564.
17.
KingsleyL, SmitE, RiddlerS. Prevalence of lipodystrophy and metabolic abnormalities in the multicenter AIDS cohort study (MACS)Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago. Virginia: Foundation for Retrovirology and Human Health, 2001[abstract 538].
18.
MahajanAP, TashimaKT, BaussermanLL, FlynnMM, CarpenterCC. Plateau in body habitus changes and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy: A 3.5-year study. J Acquir Immune Defic Syndr, 2001; 28:332–335.
19.
SchererPE, WilliamsS, FoglianoM, BaldiniG, LodishHF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem, 1995; 270:26746–26749.
20.
TsiodrasS, MantzorosC. Leptin and adiponectin in the HIV associated metabolic syndrome: Physiologic and therapeutic implications. Am J Infect Dis, 2006; 2:141–152.
21.
SutinenJ, KorsheninnikovaE, FunahashiT, MatsuzawaY, NymanT, Yki-JärvinenH. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab, 2003; 88:1907–1910.
22.
AddyCL, GavrilaA, TsiodrasS, BrodoviczK, KarchmerAW, MantzorosCS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab, 2003; 88:627–636.
23.
GervasoniC, RidolfoAL, TrifiròG, SantambrogioS, NorbiatoG, MusiccoM, ClericiM, GalliM, MoroniM. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS, 1999; 13:465–471.
24.
LihnAS, RichelsenB, PedersenSB, HaugaardSB, RathjeGS, MadsbadS, AndersenO. Increased expression of TNF-α, IL-6 and IL-8 in HALS: Implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab, 2003; 285:e1072–1080.
25.
BruunJM, LihnAS, VerdichC, PedersenSB, ToubroS, AstrupA, RichelsenB. Regulation of adiponectin by adipose tissue-derived cytokines: In vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab, 2003; 285:e527–533.
26.
JonesSP, JannehO, BackDJ, PirmohamedM. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther, 2005; 10:207–213.
27.
KosmiskiL, KuritzkesD, LichtensteinK, EckelR. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther, 2003; 8:9–15.
28.
MynarcikDC, CombsT, McNurlanMA, SchererPE, KomaroffE, GelatoMC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr, 2002; 31:514–520.
29.
DubéMP, KomarowL, MulliganK, GrinspoonSK, ParkerRA, RobbinsGK, RoubenoffR, TebasP. the Adult Clinical Trials Group 384. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr, 2007; 45:508–514.
30.
JolyV, FlandreP, MeiffredyV, LeturqueN, HarelM, AboulkerJP, YeniP. Increased risk of lipoatrophy under stavudine in HIV-1 infected patients: Results of a substudy from a comparative trial. AIDS, 2002; 16:2447–2454.
31.
van derVM, CasulaM, RuiterJP. Relation between use of nucleoside reverse transcriptase inhibitors, mitochondrial DNA depletion, and severity of lipoatrophy: Results from a randomized trial comparing stavudine and zidovudine-based antiretroviral therapy. Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston. Virginia: Foundation for Retrovirology and Human Health, 2003; 323[abstract 739].
32.
LichtensteinKA, WardDJ, MoormanAC, DelaneyKM, YoungB, PalellaFJJr, RhodesPH, WoodKC, HolmbergSD. the HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS, 2001; 15:1389–1398.
33.
LichtensteinKA, DelaneyKM, ArmonC, WardDJ, MoormanAC, WoodKC, HolmbergSD. the HIV Outpatient Study Investigators. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr, 2003; 32:48–56.
